Achaogen Up In IPO

South San Francisco-based Achaogen raised $72M in its IPO, and was up in trading during the day, after debuting at $12 per share this morning on the NASDAQ Global Market as AKAO. The company, which develops antibiotics aimed at drug-resistant infections, priced at $12.00 per share last night, at the high end of its initial $10.00 to $12.00 per share range. Achaogen was venture backed by Domain Associate,s Venrock, The WellCome Trust, Arch Venture Partners, Versant Ventures, Omega Fund, 5AM Ventures, as well as others.